PMID- 30573348
OWN - NLM
STAT- MEDLINE
DCOM- 20200226
LR  - 20200226
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 13
IP  - 3
DP  - 2019 Jun
TI  - Health-related quality of life in adults with type 2 diabetes mellitus starting 
      with new glucose lowering drugs: An inception cohort study.
PG  - 221-232
LID - S1751-9918(18)30151-7 [pii]
LID - 10.1016/j.pcd.2018.11.009 [doi]
AB  - AIMS: To assess baseline and change after 26-weeks in health-related quality of 
      life (HRQoL) among adults with type 2 diabetes mellitus (T2DM) initiating one of 
      the new glucose lowering drugs (GLD) in daily practice. METHODS: Inception cohort 
      of patients who initiated one of dipeptidyl peptidase 4 inhibitors (DPP-4), 
      glucagon-like peptide-1 analogues (GLP-1) or sodium-glucose cotransporter 
      inhibitors (SGLT2) drugs. A baseline questionnaire collected socio-demographic 
      and self-reported clinical data. HRQoL was assessed by the Euroqol-5D. 
      Participants were divided into: (1) incident new users (INU) (who used for the 
      first time one of the monitored GLD and had no current or prior experience with 
      DPP-4/GLP-1/SGLT2) and (2) prevalent new users (PNU) (who had previously used at 
      least one GLD of the monitored drug classes, but not the inception drug). 
      Multivariate regression explored factors associated with a meaningful change in 
      HRQoL. RESULTS: 1303 patients. Over 26weeks, a mean positive change in the EQ-5D 
      scores, were observed. No differences between INU and PNU were found. 
      Participants with worse health conditions (e.g. presence and number of chronic 
      diseases, obese) at baseline were more likely to experience larger improvements 
      in HRQoL. CONCLUSIONS: Over 26-weeks, T2DM patients starting with, or switching 
      to new GLD maintained or modestly increased their HRQoL.
CI  - Copyright (c) 2018 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Torre, Carla
AU  - Torre C
AD  - Centre for Health Evaluation & Research (CEFAR), National Association of 
      Pharmacies, Lisboa, Portugal; Research Institute for Medicines (iMed.ULisboa), 
      Faculty of Pharmacy, University of Lisbon, Lisboa, Portugal. Electronic address: 
      carla.torre@campus.ul.pt.
FAU - Guerreiro, Jose
AU  - Guerreiro J
AD  - Centre for Health Evaluation & Research (CEFAR), National Association of 
      Pharmacies, Lisboa, Portugal.
FAU - Longo, Patricia
AU  - Longo P
AD  - Centre for Health Evaluation & Research (CEFAR), National Association of 
      Pharmacies, Lisboa, Portugal.
FAU - Raposo, Joao Filipe
AU  - Raposo JF
AD  - Nova Medical School, New University of Lisbon, Lisboa, Portugal; Portuguese 
      Diabetes Association (APDP), Lisboa, Portugal.
FAU - Leufkens, Hubert
AU  - Leufkens H
AD  - Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for 
      Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
FAU - Martins, Ana Paula
AU  - Martins AP
AD  - Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University 
      of Lisbon, Lisboa, Portugal; Faculty of Pharmacy, University of Lisbon, Lisboa, 
      Portugal.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20181217
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Substitution
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Incretins/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Portugal
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Clinical pharmacology
OT  - Cohort studies
OT  - Diabetes mellitus
OT  - Quality of life
OT  - Surveys and questionnaires
OT  - Therapeutics
OT  - Type 2
OT  - Type 2/drug therapy
EDAT- 2018/12/24 06:00
MHDA- 2020/02/27 06:00
CRDT- 2018/12/22 06:00
PHST- 2018/06/07 00:00 [received]
PHST- 2018/11/06 00:00 [revised]
PHST- 2018/11/15 00:00 [accepted]
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2020/02/27 06:00 [medline]
PHST- 2018/12/22 06:00 [entrez]
AID - S1751-9918(18)30151-7 [pii]
AID - 10.1016/j.pcd.2018.11.009 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2019 Jun;13(3):221-232. doi: 10.1016/j.pcd.2018.11.009. Epub 
      2018 Dec 17.